TAR-200 alone was compared with TAR-200 in combination with a PD-1 inhibitor to determine the efficacy of the treatment.
Non-Muscle Invasive Urothelial Carcinoma
Latest News
A deep learning model can be used to efficiently compare the outcomes of patients with NMIBC undergoing various treatments.
Drs. Ahdoot, Yerram discusses trial data, early adoption, and why en bloc TURBT is a safe option worth trying in practice.
Drs. Ahdoot, Yerram review trial data and share practical tips for adopting en bloc TURBT across real-world settings.
Drs. Ahdoot and Yerram weigh how to approach tumors located in challenging areas, and the role of detrusor muscle sampling.
Drs. Ahdoot and Yerram discuss the fundamental reasons for adopting en bloc resection in bladder cancer surgery.
Researchers find promise in Gem/Doce as an alternative therapy for patients with NMIBC recurrence after BCG induction.
Urothelial Carcinoma Knowledge Hubs
Curated clinical content based on urothelial cancer types, therapies, and technologies
Conference Coverage
At the Oncology Forum, Dr. Sanjay Juneja led a dynamic discussion covering pivotal developments across genitourinary cancers.
Dr. Loïc Djaileb explores the use of RECIP 1.0 criteria with SPECT/CT and the efficacy of this strategy in monitoring mCRPC.
Drs. Tagawa and Marulanda Corzo discuss the use of single time-point SPECT/CT dosimetry for 177Lu-PSMA targeted RLT.
Dr. Nadine Mallak talks about 18F-fluciclovine to detect disease in BCR of prostate cancer when the standard of care fails.
Dr. Miles highlights the dilemma of managing PC with BCR after prostatectomy but no visible disease on standard imaging.
Dr. Kimura shares insights on PSMA PET/CT metrics and their potential role in guiding treatment decisions for mCRPC.
Section Editor
Sia Daneshmand, MDEditor | Professor of Urology and Medicine (Oncology) at the University of Southern California
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.